Megan R W Barber1, John G Hanly2, Li Su3, Murray B Urowitz4, Yvan St Pierre5, Juanita Romero-Diaz6, Caroline Gordon7, Sang-Cheol Bae8, Sasha Bernatsky9, Daniel J Wallace10, David A Isenberg11, Anisur Rahman11, Ellen M Ginzler12, Michelle Petri13, Ian N Bruce14, Paul R Fortin15, Dafna D Gladman4, Jorge Sanchez-Guerrero4, Rosalind Ramsey-Goldman16, Munther A Khamashta17, Cynthia Aranow18, Meggan Mackay18, Graciela S Alarcón19, Susan Manzi20, Ola Nived21, Andreas Jönsen21, Asad A Zoma22, Ronald F van Vollenhoven23, Manuel Ramos-Casals24, Guillermo Ruiz-Irastorza25, S Sam Lim26, Kenneth C Kalunian27, Murat Inanc28, Diane L Kamen29, Christine A Peschken30, Soren Jacobsen31, Anca Askanase32, Chris Theriault2, Vernon Farewell3, Ann E Clarke1. 1. University of Calgary, Alberta, Canada. 2. Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. 3. MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. 4. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada. 5. Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. 6. Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico. 7. Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 8. Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. 9. McGill University Health Centre, Montreal, Quebec, Canada. 10. Cedars-Sinai/David Geffen School of Medicine at the University of California, Los Angeles. 11. University College London, London, UK. 12. State University of New York Downstate Medical Center, Brooklyn, New York. 13. Johns Hopkins University School of Medicine, Baltimore, Maryland. 14. Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, the University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 15. CHU de Québec-Université Laval, Quebec City, Canada. 16. Northwestern University and Feinberg School of Medicine, Chicago, Illinois. 17. Lupus Research Unit, The Rayne Institute, St Thomas's Hospital, King's College London School of Medicine, London, UK. 18. Feinstein Institute for Medical Research, Manhasset, New York. 19. University of Alabama at Birmingham. 20. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 21. Lund University, Lund, Sweden. 22. Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, UK. 23. Karolinska Institute, Stockholm, Sweden. 24. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain. 25. BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain. 26. Emory University School of Medicine, Atlanta, Georgia. 27. University of California Los Angeles School of Medicine, La Jolla. 28. Istanbul University, Istanbul, Turkey. 29. Medical University of South Carolina, Charleston. 30. University of Manitoba, Winnipeg, Manitoba, Canada. 31. Copenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 32. Hospital for Joint Diseases, New York University Seligman Center for Advanced Therapeutics, New York, New York.
Abstract
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling. METHODS: Patients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs associated with each renal state by the expected state duration. RESULTS: A total of 1,545 patients participated; 89.3% were women, the mean ± age at diagnosis was 35.2 ± 13.4 years, 49% were white, and the mean followup duration was 6.3 ± 3.3 years. LN developed in 39.4% of these patients by the end of followup. Ten-year cumulative costs were greater in those with LN and an estimated glomerular filtration rate (GFR) <30 ml/minute ($310,579 2015 Canadian dollars versus $19,987 if no LN and estimated GFR >60 ml/minute) or with LN and estimated proteinuria >3 gm/day ($84,040 versus $20,499 if no LN and estimated proteinuria <0.25 gm/day). CONCLUSION: Patients with estimated GFR <30 ml/minute incurred 10-year costs 15-fold higher than those with normal estimated GFR. By estimating the expected duration in each renal state and incorporating associated annual costs, disease severity at presentation can be used to anticipate future health care costs. This is critical knowledge for cost-effectiveness evaluations of novel therapies.
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling. METHODS: Patients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs associated with each renal state by the expected state duration. RESULTS: A total of 1,545 patients participated; 89.3% were women, the mean ± age at diagnosis was 35.2 ± 13.4 years, 49% were white, and the mean followup duration was 6.3 ± 3.3 years. LN developed in 39.4% of these patients by the end of followup. Ten-year cumulative costs were greater in those with LN and an estimated glomerular filtration rate (GFR) <30 ml/minute ($310,579 2015 Canadian dollars versus $19,987 if no LN and estimated GFR >60 ml/minute) or with LN and estimated proteinuria >3 gm/day ($84,040 versus $20,499 if no LN and estimated proteinuria <0.25 gm/day). CONCLUSION: Patients with estimated GFR <30 ml/minute incurred 10-year costs 15-fold higher than those with normal estimated GFR. By estimating the expected duration in each renal state and incorporating associated annual costs, disease severity at presentation can be used to anticipate future health care costs. This is critical knowledge for cost-effectiveness evaluations of novel therapies.
Authors: G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: Andreas Jönsen; Frida Hjalte; Minna Willim; Katarina Steen Carlsson; Christopher Sjöwall; Elisabet Svenungsson; Dag Leonard; Christine Bengtsson; Solbritt Rantapää-Dahlqvist; Susanne Pettersson; Iva Gunnarsson; Agneta Zickert; Johanna T Gustafsson; Lars Rönnblom; Ingemar F Petersson; Anders A Bengtsson; Ola Nived Journal: Semin Arthritis Rheum Date: 2015-12-02 Impact factor: 5.532
Authors: Ginger Carls; Tracy Li; Pantelis Panopalis; Shaohung Wang; Amy G Mell; Teresa B Gibson; Ron Z Goetzel Journal: J Occup Environ Med Date: 2009-01 Impact factor: 2.162
Authors: D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma Journal: Arthritis Rheum Date: 1996-03
Authors: John G Hanly; Aidan G O'Keeffe; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Michelle Petri; Ian N Bruce; Mary Anne Dooley; Rosalind Ramsey-Goldman; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Kristjan Steinsson; Ola Nived; Gunnar K Sturfelt; Susan Manzi; Munther A Khamashta; Ronald F van Vollenhoven; Asad A Zoma; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Thomas Stoll; Murat Inanc; Kenneth C Kalunian; Diane L Kamen; Peter Maddison; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell Journal: Rheumatology (Oxford) Date: 2015-09-05 Impact factor: 7.580
Authors: George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas Journal: Ann Rheum Dis Date: 2012-07-31 Impact factor: 19.103
Authors: Henrik Christian Bidstrup Leffers; Anne Troldborg; Anne Voss; Salome Kristensen; Jesper Lindhardsen; Prabhat Kumar; Asta Linauskas; Lars Juul; Niels Steen Krogh; Bent Deleuran; Lene Dreyer; Søren Jacobsen Journal: Lupus Sci Med Date: 2021-04
Authors: Olena Mandrik; James Fotheringham; Shijie Ren; Jeffrey A Tice; Richard H Chapman; Matthew D Stevenson; Steven D Pearson; Serina Herron-Smith; Foluso Agboola; Praveen Thokala Journal: Clin J Am Soc Nephrol Date: 2022-02-03 Impact factor: 10.614
Authors: Laura Bartels-Peculis; Ajay Sharma; Alison M Edwards; Anirudh Sanyal; Erin Connolly-Strong; Winnie W Nelson Journal: Open Access Rheumatol Date: 2020-06-22
Authors: Alexandra Legge; Susan Kirkland; Kenneth Rockwood; Pantelis Andreou; Sang-Cheol Bae; Caroline Gordon; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Daniel J Wallace; Sasha Bernatsky; Ann E Clarke; Joan T Merrill; Ellen M Ginzler; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; David A Isenberg; Anisur Rahman; Graciela S Alarcón; Michelle Petri; Munther A Khamashta; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Ronald F van Vollenhoven; Andreas Jonsen; Ola Nived; Manuel Ramos-Casals; Diane L Kamen; Kenneth C Kalunian; Søren Jacobsen; Christine A Peschken; Anca Askanase; John G Hanly Journal: Arthritis Care Res (Hoboken) Date: 2022-02-17 Impact factor: 5.178